Literature DB >> 6222116

Production of a human T lymphocyte chemotactic factor by T cell subpopulations.

D E Van Epps, J W Potter, D A Durant.   

Abstract

Concanavalin A-stimulated human peripheral blood mononuclear cells release a lymphocyte chemotactic factor. This lymphocyte chemotactic factor is produced optimally after 24 to 48 hr of culture and is not found before 3 hr of culture, which suggests that the factor is synthesized de novo and is not preformed and secreted after Con A stimulation. This is further supported by experiments showing that the protein synthesis inhibitors cycloheximide and puromycin totally prevent the production of the chemotactic factor. Experiments using cultured and uncultured T lymphocytes as responding cells show that cultured T cells respond more efficiently than uncultured T cells to this factor. Furthermore, the lymphocyte chemotactic factor preferentially stimulates T lymphocyte locomotion as compared to peripheral blood non-T lymphocyte migration. Fractionation of mononuclear cells into glass nonadherent lymphocytes, monocyte-enriched preparations, T lymphocytes, and non-T lymphocytes shows that lymphocyte chemotactic factor is produced by Con A-stimulated, glass nonadherent lymphocytes and T cells but not by monocytes or non-T lymphocytes. Further fractionation of T lymphocytes into Leu-2 and Leu-3 T cell subpopulations shows that the production of T lymphocyte chemotactic factor can be attributed to the Leu-2 suppressor/cytotoxic T cell subset. The generation of a T lymphocyte chemotactic factor by Leu-2 T cells may represent a means of recruiting other T cells to the site of its release.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6222116

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Increased levels of interleukin-16 in the airways of tobacco smokers: relationship with peripheral blood T lymphocytes.

Authors:  M Laan; I Qvarfordt; G C Riise; B A Andersson; S Larsson; A Lindén
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

2.  The locomotor capacity of human lymphocytes and its enhancement by cell growth.

Authors:  P C Wilkinson
Journal:  Immunology       Date:  1986-02       Impact factor: 7.397

3.  Mechanisms of lymphocyte adhesion to human vascular endothelial cells in culture. T lymphocyte adhesion to endothelial cells through endothelial HLA-DR antigens induced by gamma interferon.

Authors:  J Masuyama; N Minato; S Kano
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

4.  OKT3-activated locomotion of human blood lymphocytes: a phenomenon requiring contact of T cells with Fc receptor-bearing cells.

Authors:  P C Wilkinson; A Higgins
Journal:  Immunology       Date:  1987-03       Impact factor: 7.397

Review 5.  The role of lymphokines in delayed-type hypersensitivity reactions.

Authors:  C L Geczy
Journal:  Springer Semin Immunopathol       Date:  1984

6.  Alterations in neutrophil superoxide production following piroxicam therapy in patients with rheumatoid arthritis.

Authors:  D E Van Epps; S Greiwe; J Potter; J Goodwin
Journal:  Inflammation       Date:  1987-03       Impact factor: 4.092

Review 7.  Role of endothelium in chronic inflammation.

Authors:  M Ziff
Journal:  Springer Semin Immunopathol       Date:  1989

8.  IL-16 in the airways of lung allograft recipients with acute rejection or obliterative bronchiolitis.

Authors:  M Laan; A Lindén; G C Riise
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

9.  In vivo effects of a single infusion of theophylline on human peripheral blood lymphocytes.

Authors:  R Pardi; M R Zocchi; E Ferrero; G F Ciboddo; L Inverardi; C Rugarli
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

10.  Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant.

Authors:  M W Carr; S J Roth; E Luther; S S Rose; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.